Lynch syndrome
In a trial of 23 Lynch syndrome patients, those who received the vaccine and developed neoantigen-specific T cells had a higher chance of remaining disease-free over 10 years.
Genetic Testing Challenges in Oncology: Lynch Syndrome Variant in Patient Lacking Family History
An unexpected, deleterious MSH6 variant was found in a patient seeking preimplantation genetic testing due to relatives with cancer and a familial BRCA2 variant.
Genetic Testing Challenges in Oncology: Full Family History Helps ID Lynch Syndrome Founder Variant
In a family with a known cancer variant, genetics experts are proficient in determining whether single-site testing or panel testing is more appropriate.
The Swiss biotech is developing a personalized neoantigen vaccine and working with the NCI to test the ability of an off-the-shelf vaccine to prevent cancer in those with Lynch syndrome.
Nouscom Closes $72M Series C Funding Round
The firm plans to put the proceeds from the oversubscribed financing toward advancing its off-the-shelf and bespoke neoantigen cancer vaccines.